Literature DB >> 3318048

United States Public Health Service Tuberculosis Therapy Trial 21: preliminary results of an evaluation of a combination tablet of isoniazid, rifampin and pyrazinamide.

L J Geiter1, R J O'Brien, D L Combs, D E Snider.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3318048     DOI： 10.1016/0041-3879(87)90021-3

Source DB:  PubMed          Journal:  Tubercle        ISSN： 0041-3879


× No keyword cloud information.
  9 in total

Review 1.  The Bewildering Antitubercular Action of Pyrazinamide.

Authors:  Elise A Lamont; Nicholas A Dillon; Anthony D Baughn
Journal:  Microbiol Mol Biol Rev       Date:  2020-03-04       Impact factor: 11.056

Review 2.  Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis.

Authors:  Carmen R Gallardo; David Rigau Comas; Angélica Valderrama Rodríguez; Marta Roqué i Figuls; Lucy Anne Parker; Joan Caylà; Xavier Bonfill Cosp
Journal:  Cochrane Database Syst Rev       Date:  2016-05-17

3.  Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of the British Thoracic Society.

Authors: 
Journal:  Thorax       Date:  1998-07       Impact factor: 9.139

Review 4.  Fixed-dose combination drugs for tuberculosis: application in standardised treatment regimens.

Authors:  Bjørn Blomberg; Bernard Fourie
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  Effectiveness of RHZE-FDC (fixed-dose combination) compared to RH-FDC + Z for tuberculosis treatment in Brazil: a cohort study.

Authors:  José Ueleres Braga; Anete Trajman
Journal:  BMC Infect Dis       Date:  2015-02-21       Impact factor: 3.090

Review 6.  The Effect on Treatment Adherence of Administering Drugs as Fixed-Dose Combinations versus as Separate Pills: Systematic Review and Meta-Analysis.

Authors:  Katy A van Galen; Jeannine F Nellen; Pythia T Nieuwkerk
Journal:  AIDS Res Treat       Date:  2014-09-04

Review 7.  Bioenergetic Inhibitors: Antibiotic Efficacy and Mechanisms of Action in Mycobacterium tuberculosis.

Authors:  Erik J Hasenoehrl; Thomas J Wiggins; Michael Berney
Journal:  Front Cell Infect Microbiol       Date:  2021-01-11       Impact factor: 5.293

Review 8.  Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives.

Authors:  Madhuri Devabhaktuni; Sripal Bangalore
Journal:  Vasc Health Risk Manag       Date:  2009

Review 9.  Impact of the host environment on the antitubercular action of pyrazinamide.

Authors:  Elise A Lamont; Anthony D Baughn
Journal:  EBioMedicine       Date:  2019-10-25       Impact factor: 8.143
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.